10-Q/A: AI Tech Group Faces Mounting Losses, Going Concern Warning

AI Technology Group Inc. filed an amended quarterly report revealing increased operating losses, a significant working capital deficit, and substantial doubt about its ability to continue as a going concern.

Summary

• Filed an amended Form 10-Q to comply with Section 12(g) of the Securities Exchange Act of 1934, indicating its status as a non-shell company.
• Reported no revenue for the three and nine months ended September 30, 2025, and 2024.
• Net loss for the three months ended September 30, 2025, was $29,628, a significant increase from $750 in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $33,889, up from $1,962 in the prior year period.
• Accumulated deficit reached $4,388,733 as of September 30, 2025.
• Working capital deficit was $75,176 as of September 30, 2025.
• The company has substantial doubt about its ability to continue as a going concern due to lack of revenue and ongoing operating losses.
• Funding is expected to be sourced through private placements and advances from related parties.
• A change in control occurred on July 29, 2025, with Marcus Johnson appointed as the new President, CEO, and CFO.
• Entered into a definitive agreement on August 1, 2025, to acquire AVM Biotechnology Inc., and subsequently issued 27,958,695 restricted common shares to Biomed360 Solutions Corp. shareholders on October 7, 2025, as part of this agreement.
• Prior period financial statements for December 31, 2024, were restated to correct material errors related to prepaid expenses, related parties, common stock, additional paid-in capital, and accumulated deficit.
• Disclosure controls and procedures were deemed ineffective due to material weaknesses in internal controls over financial reporting.

Sentiment

Score: 2

Explanation: The company reported no revenue, significantly increased losses, a worsening working capital deficit, and an accumulated deficit of over $4.3 million. Auditors issued a going concern opinion, and internal controls were deemed ineffective. While there's a proposed acquisition, its success is uncertain, and the company relies heavily on related party funding, indicating severe financial instability and high operational risk.

Positives

• Successfully clarified non-shell company status with the SEC, addressing a compliance requirement.
• Secured financing through advances from related parties, totaling $20,644 for the nine months ended September 30, 2025, and an additional $18,996 subsequent to the period, providing short-term liquidity.
• Entered into a definitive agreement on August 1, 2025, for the proposed acquisition of AVM Biotechnology Inc., indicating a potential strategic pivot and future business direction.
• Issued 27,958,695 restricted common shares to Biomed360 Solutions Corp. shareholders on October 7, 2025, progressing the acquisition agreement.

Negatives

• No revenue generated from operations for the three and nine months ended September 30, 2025, and 2024.
• Significant increase in net loss for the three months ended September 30, 2025, to $29,628 from $750 in the prior year.
• Substantial increase in net loss for the nine months ended September 30, 2025, to $33,889 from $1,962 in the prior year.
• Accumulated deficit grew to $4,388,733 as of September 30, 2025.
• Working capital deficit of $75,176 as of September 30, 2025, indicating a deteriorating liquidity position.
• Auditors issued a going concern opinion, highlighting substantial doubt about the company's ability to continue operations for the next twelve months without additional capital.
• Disclosure controls and procedures were deemed ineffective due to material weaknesses in internal controls over financial reporting, signaling significant governance and oversight issues.
• Reliance on related party advances for funding, which are unsecured and non-interest-bearing with no set repayment terms, poses a risk to long-term financial stability.
• The proposed acquisition of AVM Biotechnology Inc. has no assurance of closing, introducing uncertainty to future strategic plans.

Risks

• **Going Concern**: Substantial doubt exists regarding the company's ability to continue as a going concern due to no revenues, accumulated operating losses of $4,388,733, and a working capital deficit of $75,176.
• **Funding Dependence**: The company is entirely dependent on raising additional capital through private placements and advances from related parties to fund operations and achieve profitability, with no guarantee of success.
• **Operational Ineffectiveness**: Disclosure controls and procedures were not effective as of September 30, 2025, due to material weaknesses in internal controls over financial reporting, which could lead to errors or fraud.
• **Acquisition Uncertainty**: There is no assurance that the proposed acquisition of AVM Biotechnology Inc. will close, despite the definitive agreement, potentially impacting the company's strategic direction.
• **Related Party Reliance**: Heavy reliance on unsecured, non-interest-bearing advances from related parties for liquidity is not a sustainable long-term financing strategy and introduces potential conflicts of interest.
• **Historical Performance**: The company has a history of changing business purposes and ceasing operations (e.g., real estate development in 2009), indicating potential instability in its business model.

Future Outlook

The company anticipates requiring additional funding to meet ongoing obligations and fund anticipated operating losses. It intends to fund its business through private placements and advances from related parties. No substantial revenues are expected until the company's plan of operations is fully implemented. The proposed acquisition of AVM Biotechnology Inc. is subject to customary closing conditions, and there is no assurance that this transaction will be completed.

Management Comments

• "The Company will require additional funding to meet its ongoing obligations and to fund anticipated operating losses."
• "The ability of the Company to continue as a going concern is dependent on raising capital to fund its initial business plan and ultimately to attain profitable operations."
• "The Company intends to continue to fund its business by way of private placements and advances from related parties as may be required."
• "No substantial revenues are anticipated until we have implemented our plan of operations."
• "Our auditors have issued a going concern opinion, meaning that there is substantial doubt if we can continue as an on-going business for the next twelve months unless we obtain additional capital."
• "Our disclosure controls and procedures were not effective due to the existence of material weaknesses in our internal controls over financial reporting."

Industry Context

AI Technology Group Inc. is a pre-revenue development-stage company with a history of shifting business focuses, from electromagnetic motors to real estate, and now ostensibly AI technology, with a proposed pivot into biotechnology via acquisition. This pattern is common for struggling or 'shell' companies seeking a new identity and market opportunity. However, the company's lack of revenue, significant accumulated losses, and severe governance issues (ineffective internal controls) place it far behind typical industry standards for either established technology or emerging biotechnology firms. The reliance on related party funding, rather than institutional investment, further highlights its early and precarious stage, making it an outlier in competitive, capital-intensive sectors like AI or biotech.

Comparison to Industry Standards

• The company's financial performance, characterized by zero revenue, increasing losses, and a substantial accumulated deficit of $4,388,733, is significantly below industry standards for operational companies in any sector.
• For a development-stage company, while losses are common, the magnitude of the accumulated deficit and the worsening working capital deficit of $75,176, coupled with no cash, indicate a severe lack of financial resources compared to well-funded startups in the AI or biotechnology space.
• The determination that disclosure controls and procedures were ineffective due to material weaknesses in internal controls over financial reporting is a critical governance failure, falling far below acceptable standards for any publicly traded company, regardless of size, and is a red flag for investors.
• The reliance on unsecured, non-interest-bearing advances from related parties for all funding is not a sustainable or robust financing strategy compared to the diverse capital sources (e.g., venture capital, strategic partnerships, public offerings) typically utilized by successful growth companies or even early-stage biotech firms like Moderna or BioNTech during their development phases.
• The company's history of changing business models and ceasing operations (e.g., real estate development in 2009) suggests a lack of consistent strategic execution, which contrasts sharply with the focused, long-term development paths seen in successful technology or biotech companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any pending legal proceedings, and no such proceedings are known to be contemplated.

Related Party Transactions

• The CEO paid expenses of $20,644 on behalf of the company during the nine-month period ended September 30, 2025.
• Total amount owed to the previous CEO as of September 30, 2025, is $67,375.
• A shareholder loan outstanding as of December 31, 2024, of $46,732 was transferred to a company controlled by the new president, Marcus Johnson.
• The company's president paid invoices of $18,996 subsequent to the period, with a total amount owing to the president of $80,299 as of November 14, 2025.
• All amounts due to related parties are unsecured, non-interest-bearing, and have no set terms of repayment.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from future capital raises, potential loss of investment due to going concern issues, and uncertainty regarding the success of the proposed acquisition. The stock price is highly likely to be negatively impacted by the poor financial performance and governance issues.
• **Creditors**: Those providing advances (primarily related parties) face high risk of non-repayment given the company's financial distress, lack of revenue, and the unsecured, non-interest-bearing nature of the loans.
• **Employees**: (If any beyond management) Face job insecurity due to the company's precarious financial position and substantial doubt about its ability to continue as a going concern.
• **Customers/Suppliers**: (Currently none as pre-revenue) Future customers and suppliers would face high counterparty risk if the company were to become operational without significant financial stabilization and improved governance.

Next Steps

• Secure additional funding through private placements and advances from related parties to sustain operations.
• Implement the initial business plan to generate revenue and move towards profitable operations.
• Address and remediate the identified material weaknesses in internal controls over financial reporting.
• Work towards closing the proposed acquisition of AVM Biotechnology Inc., including providing required convertible loans.

Key Dates

Recommendation

The company is a pre-revenue entity with a history of operational cessation, reporting significantly increased losses, a substantial accumulated deficit, and a worsening working capital deficit. Auditors have issued a going concern opinion, indicating a high risk of business failure. Furthermore, material weaknesses in internal controls over financial reporting signal severe governance issues. While a proposed acquisition exists, its success is uncertain, and the company's reliance on related party funding is unsustainable. These factors collectively point to extreme financial instability and operational risk, making the stock a highly speculative and risky investment with a strong likelihood of further value erosion.

Keywords

AI Technology Group, AIPG, 10-Q/A, Quarterly Report, SEC filing, financial results, net loss, going concern, working capital deficit, related party transactions, management change, Marcus Johnson, AVM Biotechnology, Biomed360 Solutions, acquisition, internal controls, financial reporting, non-shell company, Nevada corporation